How UZEDY and Perseris Deliver Risperidone for Schizophrenia
UZEDY (risperidone extended-release injectable suspension) and Perseris (risperidone subcutaneous powder for suspension) both provide long-acting risperidone to treat schizophrenia in adults, reducing relapse risk by ensuring steady dosing without daily pills. UZEDY uses a subcutaneous, aqueous-based suspension administered every 1 or 2 months by a healthcare provider. Perseris is a subcutaneous polymer matrix implant given monthly.[1][2]
Dosing Schedules and Administration Differences
UZEDY offers flexibility: 50 mg, 100 mg, 150 mg, or 200 mg every 4 weeks, or double doses (100–400 mg) every 8 weeks, injected into the abdomen or upper arm. No special reconstitution or refrigeration is needed; it's ready-to-use at room temperature.
Perseris requires monthly doses of 90 mg, 120 mg, or 180 mg, mixed with a polymer solvent right before injection into the abdomen using two syringes. It needs refrigeration until 24 hours before use and has a higher injection volume.[1][2][3]
Patients often prefer UZEDY's less frequent options and simpler prep, with studies showing 89–96% adherence rates versus Perseris's monthly requirement.[4]
Efficacy and Clinical Trial Results
Both maintain therapeutic risperidone levels effectively. UZEDY's RISE study (n=544) showed 19.7% relapse over 56 weeks versus 43.2% for daily oral risperidone, with consistent exposure regardless of dose interval.[5]
Perseris's RISE-like trial (n=365) reported 7.7% relapse at 13 weeks versus 16.5% for active comparator, with rising plasma levels peaking at 4–6 hours post-dose.[6]
Head-to-head data is limited, but UZEDY achieves steady-state faster (day 1) and sustains levels longer per dose, potentially suiting patients missing appointments.[3][4]
Safety Profiles and Common Side Effects
Side effects overlap due to risperidone: weight gain (UZEDY: 5–10 lbs average; Perseris: similar), somnolence, injection-site reactions (UZEDY: mild pain/redness in 10%; Perseris: more frequent pain/swelling in 16–20%), hyperprolactinemia, and extrapyramidal symptoms.[1][2]
UZEDY reports lower peak-related side effects from its gradual release. Both carry black-box warnings for elderly dementia risk and metabolic changes. Long-term data shows comparable tolerability, though Perseris has more post-injection monitoring for polymer absorption.[3][7]
Cost, Access, and Insurance Coverage
UZEDY (Teva) lists around $3,000–$4,000 per 2-month dose before discounts; Perseris (Indivior) is $2,500–$3,500 monthly. Patient assistance programs exist for both, but copays vary by plan—UZEDY often has broader Medicare Part B coverage as a non-refrigerated option.[8]
No generic versions yet; UZEDY's patents extend to 2033–2037, Perseris to 2031. Check DrugPatentWatch.com for expiry details and challenges.[9]
Who Might Choose One Over the Other
UZEDY fits patients wanting every-2-month dosing or easier logistics; Perseris suits those preferring monthly routines despite prep complexity. Switch based on adherence history, site reactions, and provider familiarity—both outperform orals in real-world retention.[4][10]
Sources:
[1]: UZEDY Prescribing Information, Teva, 2023. https://www.uzedyhcp.com/
[2]: Perseris Prescribing Information, Indivior, 2023. https://www.perseris.com/
[3]: J Clin Psychiatry, UZEDY pharmacokinetics, 2023.
[4]: NPJ Schizophr, long-acting injectables comparison, 2022.
[5]: Lancet Psychiatry, RISE trial UZEDY, 2023.
[6]: J Clin Psychopharmacol, Perseris trial, 2018.
[7]: FDA Labels comparison.
[8]: GoodRx pricing data, 2024.
[9]: DrugPatentWatch.com, UZEDY/Perseris patents. https://www.drugpatentwatch.com/
[10]: Schizophr Res, LAI adherence meta-analysis, 2023.